AstraZeneca Partners With Insitro on AI Drug Discovery for MASH, Heart Disease
The multi-year deal gives AstraZeneca exclusive worldwide rights and could pay insitro up to $1.46 billion in milestones and royalties.
- On Thursday, AstraZeneca partnered with California-based biotech company Insitro to discover and develop treatments for MASH and cardiomyopathies, complex diseases affecting the liver and heart muscle.
- Researchers have historically struggled to pinpoint root biological drivers for these complex diseases, prompting AstraZeneca to seek new approaches after failing in mid-stage MASH trials last year.
- Under the agreement, AstraZeneca will pay $40 million upfront, with Insitro eligible for about $1.5 billion in potential development and commercial milestones, plus single-digit royalties.
- Insitro will apply its "Virtual Human" AI platform to identify causal disease biology and advance targets to development-candidate stage, while AstraZeneca will run and fund all future clinical trials.
- CEO Daphne Koller said Insitro focuses on early-stage discovery, recently expanding partnerships with Bristol Myers Squibb for ALS research and Eli Lilly for AI modeling of molecular properties.
25 Articles
25 Articles
AstraZeneca Signs $40 Million insitro AI Research Deal
LONDON, October 15, 2026 — AstraZeneca agreed to pay artificial intelligence drug-discovery company insitro $40 million upfront under a collaboration targeting difficult-to-treat liver and heart diseases, with substantially larger payments dependent on future milestones. Insitro could receive up to approximately $1.46 billion in development and commercial milestones, plus potential single-digit royalties on global sales, AstraZeneca […]
AstraZeneca has entered into a collaboration agreement with artificial intelligence biotechnology company insitro to discover and develop new therapies for difficult-to-treat liver and heart diseases.
AstraZeneca taps 'Virtual Human' AI in $1.5 billion deal to develop liver, heart disease drugs
AstraZeneca will pay insitro $40 million upfront, with up to $1.46 billion in milestone payments, to use its Virtual Human AI platform to develop treatments for liver and heart diseases.
AstraZeneca strikes $40 million AI drug discovery deal with ...
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium



















